Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
During a Case-Based Roundtable® event, Stephanie A. Berg, DO, moderated a discussion on the impact of adverse events and dosing approaches on treatment of metastatic renal cell carcinoma.
Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.
Pending FDA review, TLX250-CDx awaits consideration following the successful outcomes of the phase 3 ZIRCON trial in clear cell renal cell carcinoma.
Scientists have built upon bispecific T cell engagers (BTEs) technology to develop new and improved recombinant and synthetic DNA versions of therapeutic antibodies that enhances efficacy against renal cell carcinoma.
Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.
Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.
Researchers discovered new biomarkers for predicting immune checkpoint blockade-driven benefits in advanced renal cell carcinoma patients.
KIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Using the TILs CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative as predictive biomarkers did not impact outcomes in metastatic clear cell renal cell carcinoma.
Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.